Offres de financement de thèse 2021

Nous avons pour la rentrée 2021 quatres potentielles offres de financements de thèse dans le laboratoire:

  • Rôle de molécules de co-signalisation immunitaire lymphatiques en immuno-onco-cardiologie : myocardites induites par les inhibiteurs des points de contrôle immunitaires. 
  • Impact délétère des particules d'usure des freins dans le syndrome métabolique. 
  • Un Traitement par un Antagoniste du récepteur minéralocorticoïde permet-t-il de limiter une aGgravation de l’Insuffisance Cardiaque à fraction d’éjection préservée suite à l’Ovariectomie de souris en Syndrome Métabolique ? (TRAGICO-SMet).
  •  Lactate de Sodium au cours du sepsis : (LactMet-Heart) impact métabolique sur la dysfonction cardio-vasculaire

voir plus

sEH blockade prevents cardiorenal syndrome

A recent experimental study, directed by D Guerrout, published in Front Mol Biosci , describes the beneficial cardiac impact, on both diastolic and systolic functions, of blocking soluble epoxide hydrolase (sEH) during chronic kidney disease (CKD) induced by 5/6 nephrectomy (Nx) in mice. These beneficial effects may be mediated by the prevention of endothelial dysfunction, independent from kidney preservation and antihypertensor effect. Thus, inhibition of sEH holds a therapeutic potential in preventing type 4 cardiorenal syndrome.

Finerenone beneficial impact in ovariectomized mice

A recent study, directed by A Ouvrard-Pascaud, published in ESC Heart Failure describes the beneficial impact of Mineralocorticoid receptor blockade, with finerenone, on cardiac function and exercise capacity in ovariectomized mice. Briefly, the authors evaluated whether the non-steroidal mineralocorticoid receptor antagonist finerenone limited the progression of heart failure in ovariectomized (OVX) mice with metabolic disorders. They found that Finerenone improved mitochondrial ATP production in OVX mice. In addition, weight gain, increased blood pressure, and decreased insulin and glucose tolerance developing in OVX mice were improved by finerenone. The exercise capacity was diminished in untreated OVX mice and improved with Finerenone.

Use of RAS inhibitors in patients with COVID-19

Some concerns about the prescription of drugs acting on the renin-angiotensin system (RAS) have emerged due to SARS COV2 and COVID-19 pandemic and the revelation of the fundamental role of ACE2 (angiotensin-converting enzyme 2) in COVID-19 infection. Indeed, SARS COV2 utilizes ACE2 as a membrane receptor to enter target cells. Consequently, the question arises whether RAS modulating drugs impact the risk of developing severe or fatal severe acute respiratory syndrome in case of COVID-19 infection.  Here we discuss the evidence avilable on the impact of angiotensin-converting enzyme 1 inhibitors (ACEi) versus angiotensin II type 1 receptor blockers (ARB). Based on the currently available evidences, and as recommended by several medical societies, ACEi or ARB should not be systematically discontinued because to date no safety signal was raised with the use of these drugs.

Alexandre J, Cracowski JL, Richard V, Bouhanick B; French Society of Pharmacology and Therapeutics (SFPT). Drugs acting on renin angiotensin system and use in ill patients with COVID-19. Therapie. 2020;75(4):319-325.

doi: 10.1016/j.therap.2020.05.009.. PMID: 32553503

INSERM U1096

Endothelium, Valvulopathy
& Heart Failure

Réalisation Internet Bordeaux LOGO internet bordeaux mini

Contact Us

Legal mentions